Recombinant Human Uncharacterized protein C7orf66 (C7orf66)

What is C7orf66 and why is it classified as an uncharacterized protein?

C7orf66 (Chromosome 7 Open Reading Frame 66) is a human protein-coding gene located on chromosome 7 that produces a protein whose structure and function remain largely unknown. The term "uncharacterized" indicates that despite being identified through genomic sequencing, the protein's biological role, molecular function, subcellular localization, and interaction partners have not been thoroughly defined through experimental validation.

This classification represents a significant research opportunity in the field of functional proteomics, as approximately 20% of human proteins remain uncharacterized. Recent initiatives specifically target these proteins to enhance our understanding of the complete human proteome . The characterization process typically begins with computational prediction of structural elements, followed by recombinant protein production for experimental validation of biological functions.

What expression systems are recommended for producing recombinant C7orf66 protein?

For optimal production of recombinant human C7orf66, researchers should consider multiple expression systems based on predicted protein characteristics and experimental requirements:

The choice of expression system significantly impacts protein quality. For instance, when producing other signaling proteins like Sonic Hedgehog (Shh), HEK293-expressed protein with proper post-translational modifications showed over 200-fold greater activity than E. coli-produced versions . This demonstrates how critical the expression system choice is for maintaining biological activity, especially for proteins like C7orf66 whose function remains unknown.

What quality control methods should be used to verify recombinant C7orf66 protein?

A comprehensive quality control strategy for recombinant C7orf66 should incorporate multiple analytical approaches:

• Purity Assessment: SDS-PAGE and size exclusion chromatography should demonstrate >95% purity, with results documented through gel imaging.

• Identity Confirmation: Mass spectrometry (LC-MS/MS) to verify protein sequence and identify potential modifications. Western blotting can verify immunoreactivity if antibodies are available.

• Endotoxin Testing: LAL (Limulus Amebocyte Lysate) assay should confirm endotoxin levels below 1.0 EU/μg protein to ensure experimental reliability .

• Stability Analysis: Accelerated stability studies should monitor protein integrity under various storage conditions. Properly lyophilized or optimally formulated preparations are essential for maintaining activity during shipping and storage .

• Lot-to-Lot Consistency: Each new production lot should be compared to previous standards for bioactivity, purity, and endotoxin levels to ensure experimental reproducibility .

What CRISPR-Cas9 strategies can be employed to study C7orf66 function?

CRISPR-Cas9 technology provides powerful approaches for investigating C7orf66 function through systematic genetic manipulation:

Gene Knockout Strategy:
The Broad Institute has designed specific gRNA sequences for targeting C7orf66 with minimal off-target effects . When designing knockout experiments, researchers should:

• Select at least two different gRNA constructs to increase success probability .

• Verify gRNA sequences against your target gene sequence, especially if targeting specific splice variants or exons .

• Use sequence-verified plasmids containing all required elements: U6 promoter, spacer (target) sequence, gRNA scaffold, and terminator .

Key considerations for successful C7orf66 CRISPR experiments:

• Validate knockouts through sequencing and protein expression analysis

• Consider potential compensation by paralogous genes

• Analyze phenotypes across multiple cellular processes

• Implement genome-wide screens to identify genetic interactions

Researchers should note that while a single gRNA construct may be sufficient for gene knockout, using multiple guides increases the probability of successful editing and allows for validation of phenotypes across different targeting strategies .

How can post-translational modifications of C7orf66 be identified and characterized?

Post-translational modifications (PTMs) often critically determine protein function, particularly for uncharacterized proteins. A systematic approach to C7orf66 PTM analysis should include:

• Prediction and Bioinformatic Analysis: Use computational tools to predict potential PTM sites based on sequence motifs and structural features.

• Mass Spectrometry Analysis: Employ LC/ESI-MS to identify mass shifts characteristic of modifications. This approach successfully identified both cholesterol and fatty acid modifications on recombinant Sonic Hedgehog protein, revealing critical functional elements .

• Site-Directed Mutagenesis: Create variants with modified potential PTM sites to assess functional consequences.

• Functional Comparison: Compare activity of protein expressed in different systems that support varying levels of modifications. For example, with Shh protein, naturally-modified versions showed over 14-fold higher activity than versions lacking proper modifications .

The identification of PTMs may provide crucial insights into C7orf66 function, as demonstrated with other proteins where modifications were essential for proper activity and localization.

What bioinformatic approaches can predict potential functions of C7orf66?

Given the uncharacterized nature of C7orf66, bioinformatic analyses provide essential starting points for functional hypothesis generation:

These computational approaches should inform experimental design rather than replace empirical testing. When applied systematically, they can significantly narrow the experimental search space and accelerate functional characterization.

How can researchers design effective antibodies for C7orf66 detection?

Developing specific antibodies for uncharacterized proteins presents unique challenges. For C7orf66, researchers should consider:

• Epitope Selection Strategy:

  • Analyze the predicted protein structure to identify surface-exposed regions

  • Select epitopes with minimal similarity to other proteins

  • Consider multiple epitopes across the protein to increase detection probability

• Validation Protocol:

  • Use recombinant C7orf66 as a positive control

  • Include CRISPR knockout cells as negative controls

  • Perform specificity tests including Western blotting, immunoprecipitation, and immunocytochemistry

• Cross-Reactivity Testing:

  • Test against closest homologs to ensure specificity

  • Validate across multiple cell types and tissues

The credibility of subsequent studies depends heavily on antibody specificity, making thorough validation essential before applying antibodies to biological questions.

What data management practices should researchers follow when publishing results on uncharacterized proteins?

Research on uncharacterized proteins like C7orf66 requires rigorous data management to enable reproducibility and future extensions of the work:

• Comprehensive Data Deposition: All data should be deposited in appropriate repositories. For uncharacterized proteins, this is particularly important as these datasets form the foundation for future studies.

• Data Sharing Best Practices: Data sharing in research is attributed vast potential for scientific progress, allowing reproducibility of results and reuse of data for new insights . A systematic review of scholarly articles identified that academic data sharing has received increasing attention over the past decade .

• Documentation Requirements: Document experimental protocols in detail, including expression systems, purification methods, and buffer compositions. For C7orf66, document any modifications to standard protocols required for protein stability or activity.

• Research Data Management Plan:

Proper data management practices ensure that research on uncharacterized proteins builds a reliable foundation for the field and accelerates the pace of discovery .

What experimental approaches can identify potential binding partners of C7orf66?

Identification of interaction partners represents a critical step toward understanding the function of uncharacterized proteins:

• Affinity Purification-Mass Spectrometry (AP-MS):

  • Express tagged recombinant C7orf66 in appropriate cell lines

  • Perform pulldown experiments under physiological conditions

  • Identify binding partners through mass spectrometry

  • Validate interactions through reciprocal pulldowns

• Proximity Labeling Methods:

  • Fuse C7orf66 to BioID or APEX2 proximity labeling enzymes

  • Allow in vivo labeling of proximal proteins

  • Identify labeled proteins through streptavidin pulldown and mass spectrometry

  • This approach captures transient interactions often missed by traditional methods

• Yeast Two-Hybrid Screening:

  • Use C7orf66 as bait against human cDNA libraries

  • Screen for positive interactions through reporter gene activation

  • Validate interactions in mammalian systems

• Co-localization Studies:

  • Express fluorescently tagged C7orf66 in relevant cell types

  • Perform immunofluorescence to identify co-localizing proteins

  • Confirm through super-resolution microscopy techniques

These complementary approaches provide multiple lines of evidence for potential interaction partners, addressing the challenge of identifying functions for uncharacterized proteins through their molecular associations.

How should researchers optimize storage conditions for recombinant C7orf66 protein?

Proper storage of recombinant proteins is essential for maintaining activity and experimental reproducibility:

• Formulation Development:

  • Test various buffer compositions to identify optimal stability conditions

  • Consider additives like glycerol, reducing agents, or specific ions based on initial stability studies

  • Develop specialized formulations for optimal stability, as practiced with other recombinant proteins

• Lyophilization Protocol:

  • If lyophilization is selected, optimize protocols to ensure complete reconstitution

  • Validate activity pre- and post-lyophilization to confirm preservation of function

  • R&D Systems and other manufacturers use lyophilization to ensure proteins reach researchers in perfect condition

• Stability Monitoring:

  • Implement regular testing of stored protein aliquots

  • Monitor for degradation through SDS-PAGE, activity assays, and mass spectrometry

  • Establish acceptance criteria for continued use in experiments

• Storage Recommendations:

  • For short-term storage: 4°C with appropriate stabilizers

  • For long-term storage: -80°C in small aliquots to avoid freeze-thaw cycles

  • Consider specialized storage technologies that allow refrigerator storage for up to 6 months without freezing

Careful attention to these storage considerations ensures experimental consistency and reliable results when working with sensitive recombinant proteins.

How can researchers assess the potential role of C7orf66 in disease pathways?

Investigating potential disease associations for uncharacterized proteins requires a multi-faceted approach:

• Genetic Association Studies:

  • Analyze genome-wide association study (GWAS) data for SNPs in or near the C7orf66 locus

  • Look for altered expression in disease transcriptome datasets

  • Consider rare variant analysis in sequencing data from patient cohorts

• Expression Profiling:

  • Compare C7orf66 expression across normal and pathological tissues

  • Analyze expression changes during disease progression

  • Correlate expression with clinical parameters

• Functional Rescue Experiments:

  • In cellular or animal disease models, test whether C7orf66 overexpression or suppression affects disease phenotypes

  • Use CRISPR-engineered cell lines with C7orf66 knockout to assess disease-relevant cellular processes

• Pathway Analysis:

  • Based on interaction partners and expression patterns, identify potential signaling pathways involving C7orf66

  • Test effects of C7orf66 manipulation on pathway activation using reporter assays

This systematic approach can reveal unexpected roles for uncharacterized proteins in disease mechanisms, potentially identifying new therapeutic targets.

What structural biology techniques are most appropriate for characterizing C7orf66?

Determining the structure of uncharacterized proteins presents unique challenges that can be addressed through complementary techniques:

Researchers should select techniques based on protein characteristics and specific research questions. For instance, if C7orf66 contains flexible regions or undergoes conformational changes, a combination of crystallography or Cryo-EM with SAXS or NMR might provide complementary insights into both structure and dynamics.